

ALLERGAN LAUNCHES VIVITÉ™, AN ADVANCED ANTI-AGING SKIN CARE LINE CLINICALLY SHOWN TO REDUCE FINE LINES AND WRINKLES

IRVINE, Calif., April 12, 2007 -- Allergan, Inc. (NYSE: AGN) today announced the launch of VIVITÉ™, an advanced skin care line that revitalizes and shields skin to reduce the signs of aging. A scientific advancement in skin care, VIVITÉ™ has been clinically shown to reduce fine lines and wrinkles, and is the only luxury physician-dispensed skin care line that offers proprietary GLX Technology™, which creates a highly specialized blend of hydrating glycolic acid and powerful, natural antioxidants. GLX Technology™ works to renew skin and enhance the skin's natural production of hyaluronic acid, stimulating epidermal growth factor and collagen.

Products in the VIVITÉ™ skin care line, which can be purchased without a prescription through skin care physicians nationwide, have glycolic compound concentrations of up to 20 percent, whereas most over-the-counter skin care products have only a three to 10 percent glycolic acid concentration. The physician-strength glycolic acid in VIVITÉ™ is safe for at-home use, because it undergoes a proprietary process called partial neutralization, a technology that is the result of more than 10 years of scientific study. Partial neutralization optimizes pH balance to match the natural pH of skin and allows the glycolic acid to release during an extended period of time to provide the benefits of higher concentrations of glycolic acid with minimized skin irritation.

“Glycolic acid is the key to younger, fresher looking skin. Glycolic acid has been around for centuries, but what is unique about VIVITÉ™ skin care products is that they utilize GLX Technology™, which combines glycolic acid with powerful antioxidants and advanced ingredients to produce safe and highly effective results,” says dermatologist Jeanine Downie, M.D., of Image Dermatology.

When used together, VIVITÉ™ products have been clinically shown to reduce fine lines and wrinkles. The VIVITÉ™ skin care line includes:

- Exfoliating Facial Cleanser containing 15 percent glycolic compound, salicylic acid and exfoliating microbeads to cleanse, smooth and refine skin;
- Daily Antioxidant Facial Serum containing 15 percent glycolic compound, green tea, pomegranate, chamomile and aloe to moisturize and protect skin;
- Night Renewal Facial Cream containing 20 percent glycolic compound, vitamin C, vitamin E and superoxide dismutase to reduce fine lines and wrinkles; and
- Revitalizing Eye Treatment containing 10 percent glycolic compound, caffeine, peptides and light-reflecting interference pearls to reduce puffiness around the eyes and decrease the appearance of crows feet.

Short- and long-term benefits of VIVITÉ™ were demonstrated in a clinical study of 22 women with mild to moderate photodamage. After just three weeks of use, the following results were observed:

- 22% reduction in fine lines and wrinkles;
- 36% increase in skin moisture ;
- 54% improvement in skin smoothness; and
- 65% reduction in skin dryness.

“The launch of VIVITÉ™ demonstrates Allergan’s dedication to meeting the needs of consumers and physicians with technologically-advanced and science-based skin care products,” said Bob Rhatigan, Vice President, Sales & Marketing, Allergan Facial Aesthetics. “With its extensive experience in anti-aging skin care, Allergan is committed to providing innovative and effective new products for a wide range of skin care needs.”

VIVITÉ™ is the most recent addition to Allergan’s Total Facial Rejuvenation™ portfolio. VIVITÉ™ skin care products can be used alone or in combination with other products. To customize and optimize your anti-aging skin care regimen, it is important to consult a skin care physician. Additional VIVITÉ™ information is available at www.ViviteSkinCare.com.

About Glycolic Acid

Glycolic acid is a type of alpha hydroxy acid. Alpha hydroxy acids have been used for thousands of years to create skin rejuvenating products because of their ability to exfoliate dead skin cells, resulting in healthier, younger-looking skin.

Glycolic acid is derived from sugar cane, but also can be made synthetically. Because of its smaller molecular size, glycolic acid is believed to be more effective for skin care than other alpha hydroxy acids. When used correctly, glycolic acid can improve the look and feel of skin and reduce the appearance of fine lines, wrinkles and brown or age spots.

The glycolic acid in VIVITÉ™ utilizes the proprietary buffering process called partial neutralization, which is a technology that is the result of more than 10 years of scientific study. Partial neutralization optimizes pH balance to match the natural pH of skin and allows the glycolic acid to release during an extended period of time to provide the benefits of higher concentrations of glycolic acid with minimized skin irritation.

About Allergan Medical

Allergan Medical, a division of Allergan, Inc., offers the most comprehensive, science-based, aesthetic product offerings under its Total Facial Rejuvenation™ portfolio. Allergan Medical also offers the industry's widest range of breast implant options for reconstructive and aesthetic breast surgery, and leading minimally invasive devices for obesity intervention treatment.

About Allergan, Inc.

With more than 55 years of experience providing high-quality, science-based products, Allergan, Inc., with headquarters in Irvine, California, discovers, develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics, obesity intervention and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives.

Forward-Looking Statement

This press release contains "forward-looking statements", including, among other statements, the statements by Dr. Downie and Mr. Rhatigan, statements regarding research and development outcomes, efficacy, market and product potential. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients and the potential for product failures; potential difficulties in manufacturing new products; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required to do so by law.

Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2006 Form 10-K. Copies of Allergan's press releases and additional information about Allergan is available on the World Wide Web at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 1-714-246-4636.

Allergan Contacts:

Leslie Bryant (714) 246-6948 (media)
Jim Hindman (714) 246-4636 (investors)
Joann Bradley (714) 246-4766 (investors)